Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers
Status:
Withdrawn
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this antidepressant study is to determine the efficacy of vortioxetine on
depression and cognition in 80 women with breast cancer, and to elucidate
inflammatory-mediated mechanisms by which depression and its treatment influence cancer
outcome. Our hypothesis is that effective vortioxetine antidepressant therapy in depressed
women with breast cancer will attenuate increased intermediate endpoints of inflammation that
contribute to the pathogenesis of depression, cognitive impairment, and cancer progression